EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2: A RETROSPECTIVE STUDY

Kheira REKAI¹, Terki Khadidja²

Establishment university hospital of Oran, 31000, Algeria

Abstract

Introduction: chemotherapy (CT) plus trastuzumab (H) is the standard first line treatment for HER2-positive MBC. Trastuzumab plus vinorelbine regimen is among the most active and well-tolerated options in this setting. The all-oral CT combination has shown activity and good tolerance in MBC. The aim of our study is to analyze the epidemiological and clinical data; and to evaluate effectiveness safety and tolerance of trastuzumab plus oral vinorelbine in MBC HER2+.

Methods: we retrospectively reviewed all patients with HER2+ MBC who received oral vinorelbine with trastuzumab at our institution between January 2015 and March 2019.

Vinorelbine was given as a 80mg/m² dose (following a first cycle at 60mg/m² D1&D8 every 3 weeks, trastuzumab at 8mg/kg on D1 (loading dose) then 6mg/kg iv every 3 weeks.

Results: we identified 66 patients treated from January 2015 to March 2019. Median age was 43 years (32-75) (60%≤50Y). All patients had invasive ductal histology. All tumours were HER2+ by immunohistochemistry and 65% were HR negative. Other pts characteristics were: prior (neo)adjuvant CT 80%; prior trastuzumab 55%; visceral involvement 65%; ≥2 metastatic sites 50%; median number of vinorelbine administrations 17 (range 9-32); 65% of pts received more than 6 cycles.

Adverse events: G1/2: neutropenia 25%, vomiting 15%, asthenia 10% and LVEF decline 10%.

Efficacy: objective response rate 80%, CR 15%, PR 35%, SD 30%, PD 20%. Median progression-free survival was 12 months (2, 5-34).

Conclusion: The oral regimen of vinorelbine with trastuzumab has shown high anti-tumoral efficacy in pts with HER2-positive MBC. Toxicity profile was acceptable, with in particular, a very low rate of alopecia. Full treatment could be maintained until progression of the disease in the majority of pts.

Keyword: Medical Oncology Service Oran